Skip to main content

Nudge in EHR Can Reduce Unnecessary Sentinel Lymph Node Biopsy

Medically reviewed by Carmen Pope, BPharm. Last updated on July 25, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, July 25, 2024 -- A nudge intervention in the electronic health record (EHR) targeting surgeons can reduce sentinel lymph node biopsy (SLNB) among women who meet the Choosing Wisely criteria for SLNB omission, according to a study published online July 17 in JAMA Surgery.

Neil Carleton, Ph.D., from UPMC Hillman Cancer Center in Pittsburgh, and colleagues examined whether an EHR-based nudge intervention targeting surgeons in their first outpatient visit with patients can reduce the rates of SLNB. Data were obtained for female patients meeting the Choosing Wisely criteria for omission of SLNB (aged ≥70 years with cT1 and cT2, cN0, HR+/HER2− breast cancer); a column nudge was embedded into the surgeon's schedule in the EHR for these patients. The study compared a 12-month preintervention control period with a 12-month intervention period.

The researchers found that unadjusted rates of SLNB decreased by 23.1 percentage points in the intervention period compared with the control period (decrease from 46.9 percent pre-nudge to 23.8 percent after). Following nudge deployment, there was a reduction in the rate of SLNB (adjusted odds ratio, 0.26). The intervention was scored highly by surgeons on acceptability, appropriateness, and feasibility. The intervention helped remind surgeons of potential Choosing Wisely applicability, without the need for additional clicks or actions at the patient visit, which facilitated use.

"Based on these findings, an EHR nudge is an evidence-based solution to deimplement SLNB and may be extended to other practice settings," the authors write.

One author has a patent for application-specific processing of a disease-specific semantic model instance pending with Caldex.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease

THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...

ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...

Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer

THURSDAY, June 5, 2025 -- For patients with node-positive breast cancer who become pathologically tumor-free with negative axillary nodes (ypN0) after neoadjuvant chemotherapy...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.